←Back to Expert Scholars
Translational Medicine / 转化医学CLL BTK Resistance Research
Ian Flinn
MD, PhD
🏢Sarah Cannon Research Institute🌐USA
Director, Lymphoma Research
62
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ian Flinn is a prolific lymphoma and CLL clinical researcher who has led numerous early-phase trials of novel agents. His work on BTK degraders and next-generation inhibitors has expanded the therapeutic landscape for BTK inhibitor-resistant CLL. He has been instrumental in bringing clinical trials to community oncology settings.
Share:
🧪Research Fields 研究领域
CLL early-phase trials
BTK degraders
Novel CLL agents
Lymphoma-CLL overlap
Community oncology trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ian Flinn 的研究动态
Follow Ian Flinn's research updates
留下邮箱，当我们发布与 Ian Flinn（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment